drugset / Trial / NCT00149136

Treatment of Philadelphia-Positive Acute Lymphocytic Leukemia (Ph+ ALL) in the Elderly With Imatinib Mesylate (STI571) and Chemotherapy.

NCT00149136 ↗

Phase 2 Unknown 30 enrolled Hospices Civils de Lyon
Non-randomizedSingle-groupOpen-label

Summary

ALL patients aged 55 years or older were treated with steroids during one week and Ph+ve cases were then offered a specific therapy including an induction treatment with steroids, cyclophosphamide, daunorubicin and vincristine, followed, irrespective of response to induction chemotherapy, by imatinib, 600 mg daily, combined with intermittent steroids during 2 months. Patients in complete response (CR) were then given 10 blocks of alternating chemotherapy, including 2 additional two-month blocks of imatinib, for a total treatment duration of 2 years. Therapy of occult central nervous system leukemia included 5 intrathecal injections of methotrexate and cranial irradiation. Duration of therapy : 2 years.

Timeline

Start
2002-08
Primary completion
—
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Subject Imatinib Small molecule 600 mg —